Drugs.com - Clinical Trials Clinical trial news from Drugs.com. Comprehensive, up-to-date drug news for consumers and healthcare professionals.
- Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseaseson October 29, 2024 at 10:10 pm
SAN FRANCISCO, Oct. 29, 2024. Nektar Therapeutics today announced the publication of peer-reviewed data from two Phase 1b studies in Nature Communications highlighting the efficacy, safety, and tolerability of rezpegaldesleukin in patients with...
- Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with Keytruda (pembrolizumab) After Neoadjuvant Keytruda and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)on October 28, 2024 at 7:10 pm
RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE) October 28, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), today announced the initiation of INTerpath-009, a pivotal Phase 3...
- Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticariaon October 26, 2024 at 5:10 am
HAMPTON, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive results from the Company’s Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible...
- Orexo initiates new study of OX640 in participants with allergic rhinition October 25, 2024 at 9:10 pm
UPPSALA, Sweden, Oct. 25, 2024. Orexo AB, today announces the first participants have been dosed with OX640, an intranasal rescue medication for severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine, in a new study in subjects...
- FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathyon October 24, 2024 at 11:10 pm
SEATTLE--(BUSINESS WIRE)--Oct. 24, 2024-- Omeros Corporation today announced that zaltenibart (OMS906) has received rare pediatric disease designation from the U.S. Food and Drug Administration (FDA) for the treatment of complement 3 glomerulopathy...
- NIH Clinical Trial Will Test Precision Medicine Treatments for Myeloid Cancerson October 23, 2024 at 4:10 am
Wednesday, October 23, 2024 -- The National Institutes of Health (NIH) has launched a proof-of-concept precision medicine clinical trial to test new treatment combinations targeting specific genetic changes in the cancer cells of people with acute...
- First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agoniston October 22, 2024 at 10:10 pm
AACHEN, Germany, Oct. 22, 2024 . Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and...
- Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025on October 22, 2024 at 5:10 am
RICHMOND, Calif.--(BUSINESS WIRE)--Oct. 22, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the outcome of a recent successful interaction with the U.S. FDA, providing a clear regulatory pathway to...
- Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorderon October 22, 2024 at 4:10 am
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE) October 22, 2024 -- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders...
- Darling Ingredients Announces Publication of Peer-Reviewed Collagen Peptides Study and its Impact on Post-Meal Blood Glucose Spikeson October 22, 2024 at 1:10 am
IRVING, Texas, Oct. 21, 2024. Darling Ingredients Inc. today announced the publication of preclinical and clinical studies1 in the Wiley Journal of Food Science and Nutrition, focusing on the impact of a specific collagen peptide composition on...
- Phase 2 study demonstrates the first successful clinical application of antifibrotic therapy for breast canceron October 20, 2024 at 9:10 am
SAN DIEGO, Oct. 18, 2024. MeCo Diagnostics, a venture-backed startup dedicated to unlocking a new therapeutic modality for cancer, has announced a publication in Clinical Cancer Research, the leading clinical journal of the American Association for...
- Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemiaon October 19, 2024 at 4:10 am
SAN FRANCISCO, Oct. 19, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today...
- Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48on October 19, 2024 at 3:10 am
FOSTER CITY, Calif., & RAHWAY, N.J.--(BUSINESS WIRE) October 19, 2024 -- Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new results from a Phase 2 clinical study...
- Gilead Announces Plans to Voluntarily Withdraw the U.S. Accelerated Approval for Trodelvy in Metastatic Urothelial Canceron October 18, 2024 at 1:10 am
Foster City, Calif., October 18, 2024 – Gilead Sciences, Inc. today announced plans to voluntarily withdraw the U.S. accelerated approval for Trodelvy® (sacituzumab govitecan-hziy; SG) for the treatment of adult patients with locally...
- Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndromeon October 17, 2024 at 4:10 am
CAMBRIDGE, Mass.--(BUSINESS WIRE) October 17, 2024 -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced positive topline data from the Phase 2 open-label HELIOS clinical trial of AMX0035...
- Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infantson October 17, 2024 at 3:10 am
RAHWAY, N.J., Oct. 17, 2024 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the...
- Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safetyon October 16, 2024 at 4:10 am
ALISO VIEJO, Calif.--(BUSINESS WIRE) October 16, 2024 -- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases...
- Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trialon October 16, 2024 at 12:10 am
GAITHERSBURG, Md., Oct. 16, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has placed a...
- NIH and FDA Leaders Call for Innovation in Development of Smoking Cessation Treatmentson October 15, 2024 at 10:10 pm
Tuesday, October 15, 2024 -- In a new commentary in the Annals of Internal Medicine, leaders at the National Institutes of Health (NIH) and U.S. Food and Drug Administration (FDA) highlight recommendations and opportunities to promote innovation in...
- Nipocalimab Demonstrates Sustained Disease Control in Adolescents Living with Generalized Myasthenia Gravis in Phase 2/3 studyon October 15, 2024 at 10:10 pm
SAVANNAH, Ga. (October 15, 2024) – Johnson & Johnson today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChRa positive adolescents (aged 12 – 17 years) living with generalized myasthenia...
